Vertex PharmaceuticalsVRTX
VRTX
About: Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Employees: 5,400
0
Funds holding %
of 6,814 funds
0
Analysts bullish %
of 17 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
28% more call options, than puts
Call options by funds: $938M | Put options by funds: $731M
11% more first-time investments, than exits
New positions opened: 118 | Existing positions closed: 106
8% more repeat investments, than reductions
Existing positions increased: 616 | Existing positions reduced: 573
2% more capital invested
Capital invested by funds: $114B [Q2] → $116B (+$1.8B) [Q3]
1% less funds holding
Funds holding: 1,528 [Q2] → 1,518 (-10) [Q3]
2.53% less ownership
Funds ownership: 94.89% [Q2] → 92.36% (-2.53%) [Q3]
9% less funds holding in top 10
Funds holding in top 10: 32 [Q2] → 29 (-3) [Q3]
Research analyst outlook
17 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$408
0%
upside
Avg. target
$494
21%
upside
High target
$586
43%
upside
17 analyst ratings
11 positive
65%
5 neutral
29%
1 negative
6%
Wells Fargo Mohit Bansal 38% 1-year accuracy 10 / 26 met price target | 12%upside $460 | Overweight Maintained | 10 Jan 2025 |
Truist Securities Joon Lee 49% 1-year accuracy 19 / 39 met price target | 12%upside $460 | Buy Maintained | 23 Dec 2024 |
Scotiabank Greg Harrison 48% 1-year accuracy 13 / 27 met price target | 5%upside $430 | Sector Perform Maintained | 23 Dec 2024 |
JP Morgan Jessica Fye 45% 1-year accuracy 17 / 38 met price target | 22%upside $500 | Overweight Maintained | 23 Dec 2024 |
Barclays Gena Wang 13% 1-year accuracy 4 / 31 met price target | 2%upside $418 | Equal-Weight Maintained | 20 Dec 2024 |
Financial journalist opinion
Based on 58 articles about VRTX published over the past 30 days
Neutral
Business Wire
4 hours ago
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 10:30 a.m. ET/7:30 a.m. PT. “2024 marked another year of excellent progress for Vertex, as we reached more people with CF than ever before, began a new era of commercial diversification, and advanced and b.
Positive
Zacks Investment Research
2 days ago
INCY vs. VRTX: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the better value opportunity right now?
Neutral
Business Wire
2 days ago
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
BOSTON & SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and.
Neutral
Business Wire
2 days ago
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
SHANGHAI & CAMBRIDGE, Mass. & BOSTON--(BUSINESS WIRE)--Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex's povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a recombinant fusion protein therapeutic and dual antagonist of BAFF (B cell activating factor) and.
Neutral
Accesswire
2 days ago
Levi & Korsinsky Announces an Investigation on Behalf of Vertex Pharmaceuticals Incorporated (VRTX) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Neutral
Accesswire
3 days ago
Vertex Pharmaceuticals Incorporated INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Vertex Pharmaceuticals (VRTX)
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug suzetrigine.
Positive
Finbold
4 days ago
Top pharmaceutical stocks to buy in 2025
Pharmaceutical stocks represent an interesting prospect — while it is incredibly tough to separate the wheat from the chaff, picking a winner early on is more or less a ticket to outsized returns.
Negative
Benzinga
5 days ago
Vertex Grapples With Bearish Chart As Death Cross Emerges
Vertex Pharmaceuticals Inc VRTX is grappling with bearish technical signals as its stock forms a dreaded Death Cross.
Positive
MarketBeat
5 days ago
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA approval for the first CRSPR-based gene therapy treatment for sickle cell anemia (SCA) called Casgevy, developed by Vertex Pharmaceuticals Inc. NASDAQ: VRTX.
Neutral
PRNewsWire
5 days ago
Orna Therapeutics Establishes Strategic Collaboration with Vertex Pharmaceuticals to Develop Next Generation Approaches for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)
-- Collaboration to leverage Orna's differentiated lipid nanoparticle (LNP) delivery solutions for patients with SCD and TDT -- -- Orna to receive an upfront payment and is eligible to receive potential pre-clinical, clinical, and commercialization milestone payments and royalties -- WATERTOWN, Mass. , Jan. 7, 2025 /PRNewswire/ -- Orna Therapeutics (through its wholly owned subsidiary ReNAgade Therapeutics Inc.) announced a three-year strategic research collaboration with Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) to utilize Orna's novel and proprietary LNP delivery solutions to enhance Vertex's efforts in developing next generation gene editing therapies for patients with SCD and TDT.
Charts implemented using Lightweight Charts™